Axelopran
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C26H39N3O4 |
Molar mass | 457.615 g·mol−1 |
3D model (JSmol) | |
| |
|
Axelopran (INN, USAN) (developmental code name TD-1211) is a drug which is under development by Theravance Biopharma and licensed to Glycyx for all indications. It acts as a peripherally acting
A
Recent data for axelopran in three different pre-clinical models of cancer shows that a
All three pre-clinical studies showed a significant impact of axelopran on their respective endpoints, suggesting that
Axelopran has potent
See also
[edit]References
[edit]- ^ Janku F, Johnson LK, Karp DD, Atkins JT, Singleton PA, Moss J (September 2016). "Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer". Annals of Oncology. 27 (11): 2032–2038. doi:10.1093/annonc/mdw317. PMC 6267944. PMID 27573565.
- ^ Gupta K, Kshirsagar S, Chang L, Schwartz R, Law PY, Yee D, Hebbel RP (August 2002). "Morphine Stimulates Angiogenesis by Activating Proangiogenic and Survival-promoting Signaling and Promotes Breast Tumor Growth". Cancer Research. 62 (15): 4491–4498. PMID 12154060.
- ^ Singleton PA, Lingen MW, Fekete MJ, Garcia JG, Moss J (September 2006). "Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: Role of receptor transactivation". Microvascular Research. 72 (1–2): 3–11. doi:10.1016/j.mvr.2006.04.004. PMID 16820176.
- ^ Fujioka N, Nguyen J, Chen C, Li Y, Pasrija T, Niehans G, Johnson KN, et al. (October 2014). "Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer". Anesthesia and Analgesia. 113 (6): 1353–1364. doi:10.1213/ANE.0b013e318232b35a. PMC 3725599. PMID 22003224.
- ^ Lennon FE, Mirzapoiazova T, Mambetsariev B, Poroyko VA, Salgia R, Moss J, Singleton PA (March 2014). "The Mu Opioid Receptor Promotes Opioid and Growth Factor-Induced Proliferation, Migration and Epithelial Mesenchymal Transition (EMT) in Human Lung Cancer". PLOS ONE. 9 (3): e91577. Bibcode:2014PLoSO...991577L. doi:10.1371/journal.pone.0091577. PMC 3963855. PMID 24662916.
- ^ Eisenstein TK (2019). "The Role of Opioid Receptors in Immune System Function". Frontiers in Immunology. 10: 2904. doi:10.3389/fimmu.2019.02904. PMC 6934131. PMID 31921165.
- ^ Armstrong SR, Campbell CB, Richardson CL, Vickery RG, Tsuruda PR, Long DD, et al. (June 2013). "The in vivo pharmacodynamics of the novel opioid receptor antagonist, TD-1211, in models of opioid-induced gastrointestinal and CNS activity". Naunyn-Schmiedeberg's Archives of Pharmacology. 386 (6): 471–8. doi:10.1007/s00210-013-0844-5. PMID 23512167. S2CID 15482326.
- ^ Tsuruda PR, Vickery RG, Long DD, Armstrong SR, Beattie DT (June 2013). "The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist". Naunyn-Schmiedeberg's Archives of Pharmacology. 386 (6): 479–91. doi:10.1007/s00210-013-0850-7. PMID 23549670. S2CID 18963203.